The ENSEMBLE Study with Janssen’s Ad26.COV2.S Investigational Vaccine

The Ad26.COV2.S investigational vaccine is being developed to prevent or lessen the severity of COVID-19, the disease caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The Ad26.COV2.S investigational vaccine includes bits of genetic material copied from the spikes of the SARS-CoV-2 virus. The goal is for the body to be immunized against COVID-19. The investigational vaccine does not contain the actual virus and cannot cause COVID-19. The ENSEMBLE study aims to test Janssen’s investigational vaccine in many different populations across the globe.

Visit - NCT04505722 for additional details about the Janssen COVID-19 vaccine clinical study.

What You Need To Know About The Johnson & Johnson (J&J)/Janssen Vaccine 

The J&J/Janssen vaccine requires 1 dose to prevent COVID-19 disease, hospitalization, and death. Independent experts who reviewed the safety data have concluded that the vaccine is safe.  

Read more about the J&J/Janssen vaccine.

Content last reviewed on July 15, 2021